These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33257603)

  • 41. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
    Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G
    Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-titer convalescent plasma therapy for coronavirus disease 2019 and mortality.
    Cruciani M; Bongiovanni G; Franchini M
    Transfusion; 2021 Jun; 61(6):1988-1990. PubMed ID: 33913168
    [No Abstract]   [Full Text] [Related]  

  • 43. Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin.
    Gazzaruso C; Valenti C; Coppola A; Gallotti P
    Clin Microbiol Infect; 2021 Apr; 27(4):637-638. PubMed ID: 32919071
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of Convalescent Plasma in the Management of COVID-19.
    Dandachi D; Khalaf SA
    Mo Med; 2021; 118(2):118. PubMed ID: 33840851
    [No Abstract]   [Full Text] [Related]  

  • 45. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.
    Al-Tawfiq JA; Arabi Y
    Hum Vaccin Immunother; 2020 Dec; 16(12):2973-2979. PubMed ID: 32881641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.
    O'Donnell MR; Grinsztejn B; Cummings MJ; Justman JE; Lamb MR; Eckhardt CM; Philip NM; Cheung YK; Gupta V; João E; Pilotto JH; Diniz MP; Cardoso SW; Abrams D; Rajagopalan KN; Borden SE; Wolf A; Sidi LC; Vizzoni A; Veloso VG; Bitan ZC; Scotto DE; Meyer BJ; Jacobson SD; Kantor A; Mishra N; Chauhan LV; Stone EF; Dei Zotti F; La Carpia F; Hudson KE; Ferrara SA; Schwartz J; Stotler BA; Lin WW; Wontakal SN; Shaz B; Briese T; Hod EA; Spitalnik SL; Eisenberger A; Lipkin WI
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33974559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients.
    Pal P; Ibrahim M; Niu A; Zwezdaryk KJ; Tatje E; Robinson WR; Ko L; Satyavarapu I; Jones WE; Nachabe A; Luk A; Mushatt DM; Halvorson K; Denson JL; Smith CC; Simeone F; Davis G; Gill SK; McDougal A; Vigh AS; Peterson TG; Ning B; Hu T; Socola F; Robinson J; Safah H; Saba NS
    Transfus Med; 2021 Jun; 31(3):217-220. PubMed ID: 33073895
    [No Abstract]   [Full Text] [Related]  

  • 48. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COVID-19 convalescent plasma therapy: hit fast, hit hard!
    Focosi D; Franchini M
    Vox Sang; 2021 Oct; 116(9):935-942. PubMed ID: 33794556
    [No Abstract]   [Full Text] [Related]  

  • 50. Appropriate selection of convalescent plasma donors for COVID-19.
    Tedder RS; Semple MG
    Lancet Infect Dis; 2021 Feb; 21(2):168-169. PubMed ID: 32553190
    [No Abstract]   [Full Text] [Related]  

  • 51. [COVID-19: blood sufficiency versus convalescent plasma?].
    Contreras M
    Rev Med Chil; 2020 Jun; 148(6):721-723. PubMed ID: 33480368
    [No Abstract]   [Full Text] [Related]  

  • 52. Correspondence on 'CONVALESCENT plasma for COVID-19'.
    Mungmunpuntipantip R; Wiwanitkit V
    Eur J Clin Invest; 2021 Nov; 51(11):e13677. PubMed ID: 34487554
    [No Abstract]   [Full Text] [Related]  

  • 53. How Safe Is COVID-19 Convalescent Plasma?
    Franchini M; Cruciani M
    Mayo Clin Proc; 2021 Aug; 96(8):2279-2281. PubMed ID: 34353475
    [No Abstract]   [Full Text] [Related]  

  • 54. COVID-19 convalescent plasma; time for "goal directed therapy"?
    Knudson CM; Jackson JB
    Transfusion; 2021 May; 61(5):1654-1656. PubMed ID: 33723852
    [No Abstract]   [Full Text] [Related]  

  • 55. (A Little) Clarity on Convalescent Plasma for Covid-19.
    Katz LM
    N Engl J Med; 2021 Feb; 384(7):666-668. PubMed ID: 33440086
    [No Abstract]   [Full Text] [Related]  

  • 56. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
    Majumder J; Minko T
    AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
    Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I
    Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535
    [No Abstract]   [Full Text] [Related]  

  • 58. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.
    Self WH; Stewart TG; Wheeler AP; El Atrouni W; Bistran-Hall AJ; Casey JD; Cataldo VD; Chappell JD; Cohn CS; Collins JB; Denison MR; de Wit M; Dixon SL; Duggal A; Edwards TL; Fontaine MJ; Ginde AA; Harkins MS; Harrington T; Harris ES; Hoda D; Ipe TS; Jaiswal SJ; Johnson NJ; Jones AE; Laguio-Vila M; Lindsell CJ; Mallada J; Mammen MJ; Metcalf RA; Middleton EA; Mucha S; O'Neal HR; Pannu SR; Pulley JM; Qiao X; Raval JS; Rhoads JP; Schrager H; Shanholtz C; Shapiro NI; Schrantz SJ; Thomsen I; Vermillion KK; Bernard GR; Rice TW;
    Trials; 2021 Mar; 22(1):221. PubMed ID: 33743799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comment on: Nature and Dimensions of the Systemic Hyper-inflammation and Its Attenuation by Convalescent Plasma in Severe COVID-19.
    Acosta-Ampudia Y; Rojas M; Monsalve DM; Rodríguez Y; Ramírez-Santana C; Anaya JM
    J Infect Dis; 2021 May; 223(10):1833-1834. PubMed ID: 33715012
    [No Abstract]   [Full Text] [Related]  

  • 60. A patient affected by critical COVID-19 pneumonia, successfully treated with convalescent plasma.
    Einollahi B; Cegolon L; Abolghasemi H; Imanizadeh S; Bahramifar A; Zhao S; Jafari R; Javanbakht M
    Transfus Apher Sci; 2020 Dec; 59(6):102995. PubMed ID: 33183986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.